SMi presents the launch of Cell & Gene Therapy 2018

SMi Group10 - 11 October, London, UK.
SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year's event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

The conference will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Expect over 16 presentations and case studies focused on the key aspects of GMP, bioprocessing, regulatory frameworks and new therapeutic developments in in the field of cell and gene.

Hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

  • Cell Therapy Research
  • Manufacturing Innovation
  • Global Medical Affairs
  • Regulatory Updates
  • GMP and Quality Control
  • Cell and Tissue Therapies (CART therapies, stem cells, cord blood, preclinical and clinical developments)
  • Regenerative Medicine
  • Advanced Therapy Production
  • Gene Therapy Development
  • Clinical Platform Development
  • Manufacturing
  • R&D of Cell and Gene Therapies

Chair for 2018

  • Pamela Tranter, Head of Translational Research Group, UCL

Key speakers include

  • Janet Glassford, Senior Quality Assessor (Biologicals), MHRA
  • Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
  • Kei Kishimoto, Chief Scientific Officer, SelectaBiosciences
  • Shailesh Gupta, Senior Scientist, AstraZeneca
  • Peggy Sotiropoulou, R&D Manager, Research and Development, Celyad
  • Julie Kerby, Head of Manufacturing Development, Cell and Gene Therapy Catapult
  • Lior Raviv, Vice President, Development, Pluristem
  • Diego Aridgo, R&D Rare Disease Unit Head, Chiesi
  • Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotech
  • Emanuela Cuomo, Associate Director, Discovery Sciences, Cellular Biology Team, AstraZeneca
  • Yen Choo, Founder and Executive Chairman, Plasticell
  • Ian McKay, Innovation Lead Advanced Therapies, Innovate UK

2018 featured highlights

  • Discuss the challenges of accessing patients with commercial ATMPs
  • Understand the advantages of a risk-based approach to cell and gene therapy manufacturing
  • Hear the MHRA's perspective of UK and EU regulatory affairs regarding ATMPs
  • Explore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca
  • Gain insight into GMP Manufacture of plasmid DNA at the NHSBT

View the full agenda online: www.cellandgeneconference.com/wpn

Early-bird rates

  • Register by 31 May and save £400
  • Register by 29th June and save £300
  • Register by 31st August and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...